Dyadic and Scripps Research are collaborating on rapid-response hantavirus antibody and vaccine development using Dyadic’s proprietary C1 platform for fast, scalable biologic production.
Collaboration builds on prior Andes virus work and funded pandemic preparedness programs involving Gates Foundation, CEPI & ZAPI.
Read the full announcement here:https://t.co/rMcW49Jy1N
$DYAI
Dyadic Applied BioSolutions will be participating in the upcoming Sidoti Virtual Investor Conference on May 20-21.
President & COO Joe Hazelton will present company updates and meet virtually with investors throughout the event.
https://t.co/miDrKxaXr0
#DYAI #Biotech #SyntheticBiology #PrecisionFermentation #Sidoti
Dyadic has signed an OEM distribution agreement with IBT Bioservices to commercialize Dyadic-produced recombinant proteins through IBT’s global research channels.
Initial RUO products are expected to include recombinant DNase I and transferrin—marking an important step toward product-driven revenue.
Read more: https://t.co/65woPb61yt
$DYAI #biotech #lifesciences
Dyadic (NASDAQ: $DYAI) & Fermbox Bio launch animal-origin-free Recombinant DNase I (RNase-free) — the first product under their expanded collaboration.
Research-grade available
cGMP version in development
Targeting CGT & biomanufacturing markets
#Dyadic #DNaseI#Biotech #CellAndGeneTherapy #AnimalFree #PrecisionFermentation
https://t.co/47AjgTHQu9
Dyadic (NASDAQ: DYAI) & Proliant announce the commercial launch of AlbuFree™ DX, a recombinant human albumin produced using Dyadic’s proprietary fungal expression platform.
A key milestone converting licensed programs into recurring revenue streams.
Read more:https://t.co/q8Iplqs61U
#Biotech #RecombinantProtein #CellCulture #AnimalFree #DYAI
Animal-free nutrition at scale
Dyadic and BRIG BIO team up to commercialize recombinant bovine alpha-lactalbumin for infant, medical, and healthy aging nutrition—powered by the Dapibus™ platform.
Full announcement:https://t.co/VAxnbOgGeV
#AltProteins#PrecisionFermentation #FoodTech #NutritionInnovation #DyadicBioSolutions
Dyadic expands into Japan 🇯🇵 and South Korea 🇰🇷
With Intralink, we’re bringing DNase I and Human Transferrin to Asia’s leading biologics and CGT markets.
“We see meaningful opportunities…” — Joe Hazelton
https://t.co/ElPIEhiwLW
#Biologics#CGT#AsiaBiotech#DyadicBioSolutions #RecombinantProteins
Why Dyadic for Cell Culture Media?
From recombinant transferrin to growth factors, Dyadic delivers animal-free, scalable, and consistent solutions to power your media formulations.
Designed for flexibility. Engineered for performance.
#CellCulture#RecombinantProteins #MediaOptimization #AnimalFreeBiotech #DyadicBioSolutions #Biomanufacturing #LifeScienceSolutions
Demand is rising. Costs are tight. Traditional protein production can’t keep up. Dyadic’s platform delivers high yields with industrial scalability — a better way to do recombinant production.
https://t.co/wyUPn2cj3q
#RecombinantSolutions#Biotech#ProteinProduction
Tomorrow’s nutrition is animal-free
Dyadic produces recombinant dairy proteins like alpha-lactalbumin for infant & medical nutrition.
🌱 Scalable. Affordable. Sustainable. #Dyadic.com #FoodTech#Nutrition#AltProteins#Animalfreedairy
Dyadic Applied BioSolutions (NASDAQ: DYAI) achieved key Q3 2025 milestones in partnerships with Proliant Health & Biologicals and Inzymes ApS — advancing its transition to a commercially focused biotechnology company.
https://t.co/L2tYwPU63B